Last updated: September 7, 2026
Abiraterone acetate is a mature prostate-cancer product undergoing sustained generic erosion. Niraparib tosylate remains a branded PARP-inhibitor asset, but its growth depends on ovarian-cancer maintenance, biomarker-selected prostate cancer, competitive PARP pricing, and regulatory restrictions on later-line use. Abiraterone has greater historical revenue scale, while niraparib retains higher near-term strategic value because its branded market remains less exposed to generic substitution.
How do abiraterone acetate and niraparib tosylate differ commercially?
| Attribute |
Abiraterone acetate |
Niraparib tosylate |
| Brand |
Zytiga; generic abiraterone acetate |
Zejula; niraparib component of Akeega |
| Principal originator |
Janssen Biotech, part of Johnson & Johnson |
Tesaro, acquired by GSK |
| Drug class |
CYP17 inhibitor |
PARP inhibitor |
| Main disease areas |
Metastatic castration-resistant prostate cancer |
Ovarian, fallopian-tube, primary peritoneal and selected prostate cancers |
| FDA first approval |
2011 |
2017 |
| Oral dosage form |
Tablets |
Capsules or tablets, depending on product |
| Generic status |
Broad generic competition in the United States |
No established U.S. generic market through early 2024 |
| Commercial phase |
Mature, post-patent erosion |
Branded growth and lifecycle-management phase |
| Main commercial risk |
Price compression and generic substitution |
PARP-class competition, restricted labels and future patent expiry |
| Main growth lever |
Volume in cost-sensitive markets |
Biomarker selection, combination therapy and international penetration |
Abiraterone acetate is administered with prednisone or prednisolone and has become a standard androgen-signaling inhibitor in advanced prostate cancer. Niraparib is used as a maintenance PARP inhibitor and, in combination with abiraterone and prednisone, is marketed as Akeega for certain patients with BRCA-mutated metastatic castration-resistant prostate cancer.
What is the market trajectory for abiraterone acetate?
Abiraterone’s commercial trajectory has four phases:
- Rapid adoption after its 2011 FDA approval.
- Expansion into earlier prostate-cancer treatment settings.
- Peak branded revenue before generic entry.
- Rapid price and share erosion after generic launch.
Janssen reported global Zytiga sales of approximately $1.6 billion in 2017, before the full impact of U.S. generic competition. The product became one of the largest oral oncology assets in prostate cancer because it combined oral administration, broad clinical use and a mechanism that suppressed androgen biosynthesis upstream of the androgen receptor [1].
The market then shifted toward lower-cost abiraterone products. Generic manufacturers received FDA approvals for abiraterone acetate tablets in 2018, and multiple suppliers entered through settlements or authorized-generic arrangements. The most significant economic effect was not loss of clinical relevance. It was loss of branded pricing power.
What drives abiraterone acetate demand?
Demand remains supported by:
- High prevalence of metastatic prostate cancer.
- Use in combination with androgen-deprivation therapy.
- Guideline support in metastatic hormone-sensitive and castration-resistant disease.
- Low-cost generic availability.
- Familiarity among oncologists and urologists.
- Use in countries where newer androgen-receptor inhibitors remain expensive.
Abiraterone competes with enzalutamide, apalutamide, darolutamide and chemotherapy. Its principal advantage is price after generic entry. Its disadvantages include the requirement for corticosteroid coadministration and risks related to mineralocorticoid excess, including hypertension, hypokalemia and fluid retention [2].
What is the market trajectory for niraparib tosylate?
Niraparib’s commercial trajectory is more dependent on indication selection than on broad oncology volume. Zejula initially entered a growing PARP-inhibitor market dominated by olaparib and later competed with rucaparib. Its commercial positioning has changed as regulators and physicians have focused more heavily on biomarker status and overall-survival outcomes.
GSK’s annual reports have reported Zejula sales in the range of several hundred million pounds annually. The product has remained a meaningful oncology franchise but has not reached the multibillion-dollar scale achieved by the largest PARP inhibitors or prostate-cancer hormone therapies [3].
Akeega adds a second commercial pathway. FDA approved Akeega in 2023 for adult patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer, in combination with prednisone and androgen-deprivation therapy [4]. Akeega links niraparib to the much larger prostate-cancer treatment market and to abiraterone’s established clinical infrastructure.
What limits niraparib growth?
Niraparib faces four material constraints:
- Competition from olaparib, particularly in BRCA-mutated disease.
- Restricted or withdrawn indications in some later-line ovarian-cancer settings.
- Class-wide scrutiny after survival signals in certain populations.
- Need for molecular testing and clinically appropriate patient selection.
The commercial opportunity is strongest where homologous-recombination deficiency or BRCA mutation predicts meaningful PARP sensitivity. The broader the label, the greater the regulatory and clinical risk. The narrower the label, the lower the eligible population but potentially higher treatment value per patient.
How do the revenues of abiraterone and niraparib compare?
Abiraterone generated materially higher peak revenue than niraparib because it reached a broad prostate-cancer population and benefited from rapid uptake across multiple treatment lines. Niraparib has generated a smaller but strategically important branded revenue stream.
| Commercial metric |
Abiraterone acetate |
Niraparib tosylate |
| Peak branded-product scale |
Approximately $1.6 billion in annual Zytiga sales before major U.S. generic erosion |
Several hundred million pounds in annual Zejula sales |
| Current price environment |
Generic and highly compressed |
Primarily branded, with payer and class competition |
| Volume outlook |
Stable or growing in low-cost markets |
Dependent on biomarker-defined use and label durability |
| Margin outlook |
Low for generic suppliers; declining for originator |
Higher branded margins, but subject to launch and promotional costs |
| Revenue risk |
Immediate substitution |
Medium-term patent, regulatory and competitive risk |
The products also monetize differently. Abiraterone now produces economic value through high-volume generic supply, hospital and payer access, and international markets. Niraparib produces value through branded gross-to-net pricing, combination therapy and potential expansion into biomarker-defined prostate cancer.
What patents protect abiraterone acetate?
Abiraterone’s original compound patent protection has expired or substantially expired in major markets. The key historic U.S. patent was U.S. Patent No. 5,604,213, directed to abiraterone and related steroidal compounds. Its term did not prevent the eventual development of a broad generic market.
Janssen also relied on later patents directed to formulations, dosing and methods of treatment. These included patents covering abiraterone acetate formulations with improved bioavailability and clinical use. The practical value of these patents was limited by litigation outcomes, settlements and the availability of alternative generic products.
What was the impact of Paragraph IV challenges to Zytiga?
Generic companies used Paragraph IV certifications to challenge listed Zytiga patents before their stated expiration dates. Janssen filed infringement actions against several generic applicants. These cases created a litigation framework in which launch timing depended on:
- The scope and validity of formulation claims.
- Whether the generic product practiced the asserted claims.
- Settlement terms.
- FDA approval timing.
- Potential authorized-generic supply.
The settlements allowed generic entry earlier than the expiration of every later-listed patent. As a result, the Orange Book listing did not translate into a single, enforceable market exclusivity date.
What is the Orange Book status of abiraterone acetate?
The Orange Book historically listed Zytiga patents covering the active ingredient, formulation and methods of use. Because generic approvals and settlements changed the competitive timeline, the commercially relevant question became the earliest lawful generic launch date rather than the latest listed patent expiration.
Abiraterone illustrates the distinction between nominal patent life and effective market exclusivity. A later formulation patent can remain listed while generic products enter under non-infringement, invalidity or settlement-based theories.
What patents protect niraparib tosylate?
Niraparib protection is based on a layered patent estate involving:
- The niraparib compound and salt forms.
- Pharmaceutical compositions.
- Therapeutic use in ovarian cancer.
- Biomarker-defined use.
- Combination use with abiraterone.
- Manufacturing and solid-state forms.
Tesaro, and later GSK, developed the commercial estate around niraparib and its tosylate salt. The estate is more valuable than a single compound patent because it can protect separate clinical and formulation pathways. Its strength depends on claim construction, written-description support, obviousness defenses and whether generic applicants can design around salt, dosage or combination claims.
How strong is the niraparib patent estate?
Niraparib has a stronger remaining commercial estate than abiraterone because it is a newer product and remains primarily branded. Its strongest protection is likely to come from:
- Composition-of-matter claims that cover niraparib or key salts.
- Use claims tied to ovarian-cancer maintenance.
- Combination claims covering niraparib with abiraterone and prednisone.
- Biomarker-specific claims involving BRCA or homologous-recombination deficiency.
The estate is not immune to challenge. PARP inhibitors operate in a crowded field, and generic challengers can attack obviousness, enablement, written description and claim scope. Method-of-use patents are also vulnerable when the underlying indication is already established in the scientific literature.
When does abiraterone lose exclusivity compared with niraparib?
| Product |
Exclusivity position |
Generic or biosimilar risk |
| Abiraterone acetate |
Core exclusivity has expired; generic competition is established |
High and immediate |
| Zejula |
Branded exclusivity remains dependent on patent and regulatory protection |
Medium-term generic risk |
| Akeega |
Combination-product and component-patent protection may extend commercial life |
Lower near-term risk, but patent challenges are likely |
Biosimilar risk is not relevant to either product because both are chemically synthesized small molecules. The relevant threat is generic substitution, not biosimilar interchangeability.
Niraparib’s exposure is likely to develop in stages. First, challengers may target composition or salt claims. Later, they may attack method-of-use and combination claims. A generic niraparib product could also face a narrower label that omits protected indications, depending on the Orange Book patent certifications and regulatory pathway.
What FDA regulatory issues affect niraparib?
FDA regulation has become a central commercial variable for PARP inhibitors. The agency has limited or removed some indications across the class after concerns about overall survival in certain heavily pretreated patient populations. These actions affect niraparib by narrowing the addressable market and increasing the importance of first-line and biomarker-selected use.
Zejula’s strongest regulatory position is in maintenance treatment after response or stable disease following platinum-based therapy. Akeega expands the opportunity into BRCA-mutated metastatic castration-resistant prostate cancer, where the combination of PARP inhibition and androgen-biosynthesis inhibition has a clear biological rationale [4].
Niraparib’s future value therefore depends on maintaining clinically differentiated labels rather than pursuing unrestricted use across all PARP-sensitive tumors.
Which companies compete with abiraterone and niraparib?
Abiraterone competitors
The principal branded and generic competitors include:
- Enzalutamide, marketed by Astellas and Pfizer.
- Apalutamide, marketed by Johnson & Johnson.
- Darolutamide, marketed by Bayer and Orion.
- Docetaxel and cabazitaxel.
- Multiple generic abiraterone manufacturers.
Abiraterone’s competitive advantage is cost. Enzalutamide and the newer androgen-receptor inhibitors compete on efficacy positioning, convenience, absence of chronic prednisone in some regimens, or use in earlier disease settings.
Niraparib competitors
Niraparib competes with:
- Olaparib, marketed by AstraZeneca and Merck.
- Rucaparib, marketed by Rigel following acquisition of rights from Clovis.
- Talazoparib, marketed by Pfizer in combination with enzalutamide for prostate cancer.
- Platinum chemotherapy and other maintenance strategies.
Olaparib has a strong position in BRCA-mutated ovarian, breast, pancreatic and prostate cancers. Niraparib’s differentiation rests on ovarian-cancer maintenance breadth, dosing options, and the Akeega combination.
What licensing deals and corporate transactions affect these products?
Abiraterone was developed and commercialized by Cougar Biotechnology, which Johnson & Johnson acquired in 2009. That transaction gave Janssen control of a late-stage prostate-cancer asset shortly before FDA approval.
Niraparib was developed by Tesaro. GSK acquired Tesaro in 2019 for approximately $5.1 billion, including assumed debt and other consideration. The acquisition transferred Zejula and Tesaro’s oncology pipeline to GSK and made niraparib a core component of GSK’s oncology strategy [5].
Akeega also demonstrates the value of combination-product lifecycle management. Combining niraparib with abiraterone can extend commercial relevance even after abiraterone itself becomes commoditized.
What generic launch scenarios exist?
Abiraterone acetate
The base case is continued generic price erosion with stable patient volume. Originator revenue remains limited, while generic suppliers compete on manufacturing cost, supply reliability and payer contracts.
Upside scenarios are concentrated in emerging markets where generic access expands treatment rates. Downside scenarios include further price compression, shortages, or replacement by newer androgen-receptor inhibitors in earlier treatment lines.
Niraparib tosylate
The principal launch scenarios are:
- A first generic entrant challenges the compound or salt patent and launches after settlement.
- Multiple generics enter after core patent expiry, causing rapid price erosion.
- A generic launches with a skinny label excluding protected indications.
- Combination-specific patents delay competition for Akeega even after standalone niraparib competition begins.
Manufacturing barriers are moderate. Niraparib is a synthetic small molecule, but commercial suppliers must control polymorph, salt form, impurity profile, dissolution and capsule or tablet performance. These issues can support formulation patents but rarely create the durable barrier associated with biologic manufacturing.
What is the investment outlook for abiraterone and niraparib?
Abiraterone is a cash-flow and volume story, not a conventional exclusivity-growth story. Its value lies in durable demand, low-cost production and broad international use. Investors should focus on unit volume, tender pricing, manufacturing efficiency and geographic mix.
Niraparib is an exclusivity and indication-management story. Its value depends on:
- Zejula sales retention in ovarian cancer.
- Akeega uptake in BRCA-mutated prostate cancer.
- PARP-class safety and survival data.
- GSK’s ability to defend patent claims.
- Competitive positioning against olaparib.
- Success of molecular testing and patient identification.
The financial trajectory favors abiraterone for stable high-volume generic demand and niraparib for higher-margin branded growth, but niraparib carries greater clinical, regulatory and patent execution risk.
Key Takeaways
- Abiraterone acetate has moved from a high-revenue branded product to a mature generic market.
- Zytiga’s historic peak was approximately $1.6 billion in annual global sales before major generic erosion.
- Niraparib remains primarily a branded product with annual Zejula revenue in the several-hundred-million-pound range.
- Akeega provides niraparib with a prostate-cancer growth channel linked to abiraterone.
- Neither product faces biosimilar competition because both are small-molecule drugs.
- Abiraterone’s main risk is continued price compression; niraparib’s main risks are regulatory narrowing, PARP competition and future Paragraph IV litigation.
- Generic abiraterone has a high-probability, immediate substitution profile. Generic niraparib presents a later and more patent-dependent risk.
- The strongest commercial protection for niraparib is the combination of composition, biomarker and combination-use claims.
FAQs
Is abiraterone acetate still commercially attractive after generic entry?
Yes. Generic abiraterone remains commercially attractive because prostate cancer prevalence is high, treatment duration can be substantial and manufacturing costs are manageable. Profitability depends on scale and payer access rather than branded pricing.
Is niraparib tosylate the same as niraparib?
Niraparib tosylate is a salt form of niraparib used in pharmaceutical products. The active pharmacological moiety is niraparib, while the tosylate form supports formulation and manufacturing requirements.
Can a generic manufacturer launch niraparib without challenging every patent?
Potentially. A company may submit a Paragraph IV certification, pursue a section viii statement for unpatented uses, or seek a label that omits protected indications. The commercial feasibility depends on the specific Orange Book listings and patent claims in force at filing.
Does Akeega have the same patent risk as generic abiraterone?
No. Akeega combines niraparib and abiraterone, so its protection can rely on niraparib composition, combination and method-of-use claims. Generic abiraterone alone already faces broad market competition.
Which product has the stronger long-term revenue profile?
Niraparib has the stronger branded revenue profile if Zejula retains ovarian-cancer share and Akeega expands in biomarker-selected prostate cancer. Abiraterone has the stronger low-cost volume profile but limited originator upside because generic competition is established.
References
- Johnson & Johnson. (2018). Annual report 2017.
- U.S. Food and Drug Administration. (2022). Zytiga (abiraterone acetate) prescribing information.
- GSK plc. (2024). Annual report 2023.
- U.S. Food and Drug Administration. (2023). Akeega (niraparib and abiraterone acetate) prescribing information.
- GlaxoSmithKline plc. (2019). GSK completes acquisition of Tesaro.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
